Design Therapeutics, Inc. (DSGN)
$9.78-10.36%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $611M
- Beta
- 1.69
- P/E (TTM)
- -8.29
- Short % float
- 20.13%
- Days to cover
- 8.7
- SI change
- +21.1%
- 1W
- -18.30%
- 1M
- -27.66%
- vs SPY 1W
- -18.16%
- vs SPY 1M
- -30.17%
Industry peers
FMP comparable companies · ranked by market cap
- IONSSELLIonis Pharmaceuticals, Inc.$7.5BCRISISQ 8$45.28-2.95%
- PTCTSELLPTC Therapeutics, Inc.$5.4BCRISISQ 18$64.70-4.77%
- DYNSELLDyne Therapeutics, Inc.$3.1BCRISISQ 3$16.64-4.14%
- SRPTSELLSarepta Therapeutics, Inc.$1.9BCRISISQ 13$17.85-5.33%
- STOKSELLStoke Therapeutics, Inc.$1.6BCRISISQ 10$24.74-6.83%
- WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-4.27%
- SLDBSELLSolid Biosciences Inc.$676MCRISISQ -13$6.87-13.26%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on DSGN?
- LOPJLB’s latest quantitative signal on Design Therapeutics, Inc. (DSGN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DSGN in?
- Design Therapeutics, Inc. (DSGN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Design Therapeutics, Inc. (DSGN) do?
- Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neu…